Skip to main content

Veracyte, Inc.

VCYT
Exchange
Nasdaq
Industry
Services-Medical Laboratories
SEC CIK
0001384101

In the last 90 days, Veracyte, Inc. insiders filed 0 open-market purchases and 6 sales; 370 institutions reported holding it in 13F filings for Q2 2026, worth $5.23B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Veracyte, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
6 filings
6 insiders, $1.31M in total
Insiders trading
6
Net value
−$1.31M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Veracyte, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Veracyte, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Leite JohnGlobal Chief Commercial Off124,329Sep 22, 202610
Holstein JensDirector27,471Sep 16, 20263
Wygant JonathanVP, Chief Accounting Officer43,226Sep 4, 20268
Febbo Phillip G.Chief Scientific & Med Officer133,048Sep 4, 20267
Chambers RebeccaChief Financial Officer166,025Sep 4, 20268
McGuire AnnieEVP, General Counsel131,160Sep 4, 202611
Stapley MarcChief Executive Officer432,073Sep 4, 20267
Bhanji MunaDirector42,718Sep 3, 20262
Eastham KarinDirector15,097Jun 22, 20264
Jones Evan/ FaDirector34,634Jun 15, 20263
Epstein Robert SDirector57,718Jun 15, 20263
Shafer David BrentDirector31,100Jun 15, 20261
Barr EliavDirector56,461Jun 15, 20261
Miller Thomas F.Director31,100Jun 15, 20261
Haas Kevin RichardChief Dev and Tech Officer44,221Apr 14, 20261
Bishop John LDirector33,125Jul 19, 20230
Anderson Bonnie HDirector41,377Jun 6, 20230
Kennedy Giulia CChief Scientific & Med Officer65,970Dec 8, 20220
Gordon Kevin KDirector8,720Jun 10, 20220
Nova Tina SusanPresident, CLIA U.S.76,988Mar 7, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 13, 2022 (view filing)Jun 103 daysStapley MarcChief Executive OfficerPPurchase+60.0K$16.33+$979.8K+60.1%159.8K after
Jun 10, 2022 (view filing)Jun 82 daysGordon Kevin KDirectorSSale−15.0K$18.50−$277.5K−63.2%8.72K after
Mar 9, 2022 (view filing)Mar 45 daysKennedy Giulia CChief Scientific & Med OfficerSSale−23.0K$25.12−$578.5K−27.3%61.4K afterAmended3 lots
Dec 20, 2021 (view filing)Dec 173 daysEastham KarinDirectorSSale−5.00K$45.00−$225.0K−36.4%8.72K after
Dec 8, 2021 (view filing)Dec 6-72 daysKennedy Giulia CChief Scientific & Med OfficerSSale−15.4K$37.71−$579.1K−24.3%47.9K after5 lots
Nov 3, 2021 (view filing)Nov 12 daysEastham KarinDirectorSSale−4.40K$32,978.71−$145.1M−100.0%0 after3 lotsPrice outlier
Sep 21, 2021 (view filing)Sep 174 daysAnderson Bonnie HExecutive ChairwomanSSale−2.60K$50.18−$130.5K−1.2%217.5K after
Sep 14, 2021 (view filing)Sep 104 daysAnderson Bonnie HExecutive ChairwomanSSale−1.90K$50.03−$95.1K−0.9%220.1K after
Sep 9, 2021 (view filing)Sep 7-82 daysKennedy Giulia CChief Scientific & Med OfficerSSale−13.5K$50.55−$680.2K−21.2%50.0K after3 lots
Aug 4, 2021 (view filing)Aug 22 daysEastham KarinDirectorSSale−4.40K$43.90−$193.2K−50.0%4.40K after2 lots